Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.
Eli Lilly agreed to acquire AtaiBeckley for $2.8 billion upfront, with up to $1 billion in milestone payments, according to the companies. Atai’s lead drug BPL-003 is in phase 3 for treatment-resistant depression, with Jefferies estimating peak sales of $1 billion to $2 billion. The article also notes Ark Genomic Revolution ETF trading in Atai and Compass, and highlights regulatory changes affecting psychedelic reviews.
How this was made
The 30-second read
Why it matters
For LLY and ATAI, the primary tradable catalyst is the disclosed acquisition consideration. For CMPS, the tradable catalyst is the combination of phase 3 success and a compressed FDA review pathway, though launch remains contingent on DEA rescheduling and FDA review.
Market read
This is a direct M&A catalyst for LLY and ATAI and a regulatory-clinical probability catalyst for CMPS, with sector-wide sentiment implications for TRD psychedelics.
What to watch
Deal closing risk, milestone achievability, and the DEA rescheduling dependency for Compass’s launch timeline could delay or cap upside despite favorable FDA guidance.
Background
The article links Lilly’s acquisition of AtaiBeckley to a newly favorable US regulatory posture for psychedelic drugs, including an FDA priority voucher for Compass and finalized clinical trial guidance.
Ticker impact
Eli Lilly agreed to acquire AtaiBeckley for $2.8B upfront plus up to $1B in milestones, expanding its TRD pipeline.
Moderate positive bias for LLY on deal execution expectations; larger moves more likely around deal milestones or regulatory/clinical updates.
The article provides concrete M&A consideration and links it to a newly favorable FDA regulatory posture, but it also frames Atai’s peak sales as small versus Lilly’s $65.2B revenue base.
AtaiBeckley is the acquisition target in Lilly’s $2.8B upfront deal with up to $1B additional milestone payments.
Positive near-term reaction risk, with follow-through dependent on deal closing and milestone probability.
The article states the upfront price and potential milestone structure, which are primary drivers for target-company valuation and trading.
The article says Ark Genomic Revolution sold Atai and bought Compass, citing FDA priority voucher timing and Compass’s phase 3 COMP360 progress.
Potential positive drift if investors price in faster FDA review and a successful NDA/DEA rescheduling path.
The text provides specific regulatory timing (CNPV compressing review) and clinical status (phase 3 primary endpoints met), but it is still contingent on FDA review and DEA rescheduling.
Market effects
Big pharma entry via Lilly can legitimize psychedelics as a viable regulatory pathway, potentially lifting sentiment and valuation multiples across TRD-focused developers.
Primarily US regulatory-driven (FDA/DEA), so US-listed biotech sentiment may lead.
If US review timelines compress, it can influence global development and partnering expectations for psychedelic depression therapies.
Counterpoint
Lilly’s $2.8B upfront may be less about near-term revenue and more about long-dated optionality; investors could overpay for regulatory optimism before phase 3-to-approval conversion is proven.
Key entities
- companyEli Lilly
Agreed to acquire AtaiBeckley for $2.8B upfront plus up to $1B milestones.
- companyAtaiBeckley
Target of Lilly’s acquisition; lead asset BPL-003 in phase 3 for TRD.
- companyCompass Pathways
COMP360 phase 3 TRD program met primary endpoints; FDA priority voucher and NDA timing discussed.
- regulatorFDA
Issued a National Priority Voucher and finalized psychedelic clinical trial guidance.
- regulatorDEA
Rescheduling psilocybin from Schedule I is cited as a condition for Compass’s launch readiness.
